NuCana plc (NCNA)

NASDAQ: NCNA · IEX Real-Time Price · USD
0.260
-0.052 (-16.75%)
At close: Mar 28, 2024, 4:00 PM
0.252
-0.008 (-3.08%)
After-hours: Mar 28, 2024, 7:45 PM EDT

Company Description

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer.

The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.

The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer.

The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab.

It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.

NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc
NuCana logo
Country United Kingdom
IPO Date Sep 28, 2017
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Hugh Stephen Griffith

Contact Details

Address:
3 Lochside Way
Edinburgh, X0 EH12 9DT
United Kingdom
Phone 44-0-131-357-1111
Website nucana.com

Stock Details

Ticker Symbol NCNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001709626
CUSIP Number 67022C106
ISIN Number US67022C1062
SIC Code 2834

Key Executives

Name Position
Hugh Stephen Griffith Founder, Chief Executive Officer and Executive Director
Donald Munoz Chief Financial Officer
David Harrison Head of Translational Medicine
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D. Chief Medical Officer
Prof. Christopher B. Wood FRCS, M.D., Ph.D. Chief Medical Officer
Theresa Bruce Senior Vice President of Clinical Operations
Elisabeth Oelmann Senior Vice President of Medical and Clinical Development
Martin Quinn Company Secretary

Latest SEC Filings

Date Type Title
Mar 27, 2024 F-6 POS Post-effective amendments for immediately effective filing
Mar 27, 2024 424B5 Filing
Mar 27, 2024 6-K Report of foreign issuer
Mar 20, 2024 20-F Annual and transition report of foreign private issuers
Mar 20, 2024 6-K Report of foreign issuer
Feb 27, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 26, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 16, 2023 6-K Report of foreign issuer
Nov 13, 2023 6-K Report of foreign issuer